Intranasal delivery of a monoclonal IgG1 antibody targeting mugwort pollen protected mice from allergic rhinitis and asthma ...

People with hay fever could one day benefit from a first-of-its-kind “molecular shield” that blocks pollen from entering the ...

A nasal ‘molecular shield’ developed by researchers may soon block mugwort pollen, offering relief from one of the most ...

Scientists have developed a nasal "molecular shield" that disarms pollen, blocking allergic reactions fast without the use of ...

Approximately 40% of the European population are allergic to pollen, and their symptoms cause an estimated loss of 100 ...

Researchers developed a nasal antibody that blocks mugwort pollen, a major hay fever trigger in Europe and Central Asia.

Researchers at the Kazakh National Agrarian Research University have developed a pioneering nasal treatment for hay fever ...

A “MOLECULAR shield” placed in the nose could prevent hay fever symptoms, a study suggests. Scientists have engineered an ...

The alpha-gal epitope and the anti-Gal antibody in xenotransplantation and in cancer immunotherapy. Immunol Cell Biol. 2005;83(6):674-686. Commins SP, et al. Delayed anaphylaxis, angioedema, or ...

More information: Gabriel Osborn et al, Hyperinflammatory repolarisation of ovarian cancer patient macrophages by anti-tumour IgE antibody, MOv18, restricts an immunosuppressive macrophage:Treg ...

Epsilogen’s lead product candidate, MOv18 IgE, is the first therapeutic IgE antibody to enter the clinic and encouraging data from a completed Phase I trial found it to be safe and well ...